MIUDELLA
Clinical safety rating
cautionComprehensive clinical and safety monograph for MIUDELLA (MIUDELLA).
MIUDELLA (everolimus) is an mTOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the mTOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
| Metabolism | Primarily metabolized by CYP3A4; also a substrate of P-glycoprotein (P-gp). Major metabolites include hydroxylated and demethylated products, with the parent compound being the main active moiety in plasma. |
| Excretion | Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%. |
| Half-life | Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases). |
| Protein binding | Approximately 92% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.8-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is 65-80% (first-pass metabolism); intravenous is 100%. |
| Onset of Action | Oral: 30-60 minutes; intravenously: within 5 minutes. |
| Duration of Action | Duration of action is 12-24 hours for most indications, extended in hepatic impairment due to reduced clearance. |
| Molecular Weight | 350.45 |
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
| Dosage form | SYSTEM |
| Renal impairment | GFR 30-89 mL/min: 1.5 mg/kg every 24 hours; GFR <30 mL/min: 1.5 mg/kg every 48 hours. |
| Liver impairment | Child-Pugh Class B: 1 mg/kg every 12 hours; Child-Pugh Class C: 0.5 mg/kg every 12 hours. |
| Pediatric use | Children (≥2 years): 1.5 mg/kg intravenously every 12 hours for 14 days; maximum 2 g/day. |
| Geriatric use | No specific dose adjustment; monitor renal function and reduce dose if GFR <90 mL/min. |
| 1st trimester | Avoid use during first trimester due to potential teratogenicity. |
| 2nd trimester | Use only if benefit outweighs risk; limited data available. |
| 3rd trimester | Use only if benefit outweighs risk; may cause adverse fetal effects. |
Clinical note
Comprehensive clinical and safety monograph for MIUDELLA (MIUDELLA).
| Placental transfer | Crosses placenta in animal studies; human data limited. |
| Breastfeeding | Excreted in breast milk; monitor infant for adverse effects; consider discontinuing breastfeeding or drug. |
| Lactation Rating | L4 |
| Teratogenic Risk | Pregnancy Category X. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second/third trimester: Increased risk of spontaneous abortion, intrauterine growth restriction, and oligohydramnios. Contraindicated in pregnancy. |
| Fetal Monitoring | Monitor for fetal movements, uterine growth; serial ultrasound for fetal anatomy and growth. Maternal liver function tests, complete blood count, and serum drug levels if available. Assess for signs of fetal distress. |
| Fertility Effects | May impair fertility in both sexes due to hormonal disruption; reversible upon discontinuation. In males, possible oligospermia; in females, menstrual irregularities. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to MIUDELLAPregnancy
| Precautions | Non-infectious pneumonitis: Monitor for respiratory symptoms; manage with dose reduction or interruption., Infections: Increased risk of bacterial, viral, fungal, and protozoal infections; monitor for signs and symptoms., Oral ulceration: Manage with topical treatments, dose reduction, or interruption., Renal failure: Monitor renal function; dose adjustment may be needed., Metabolic effects: Monitor blood glucose and lipids; hyperglycemia, hyperlipidemia, and hypertriglyceridemia may occur., Myelosuppression: Monitor blood counts; anemia, leukopenia, thrombocytopenia, and lymphopenia can occur., Immunizations: Avoid live vaccines during treatment., Embryo-fetal toxicity: Can cause fetal harm; advise women of reproductive potential of effective contraception. |
| Food/Dietary | Avoid grapefruit and grapefruit juice, as they may inhibit CYP3A4 metabolism and increase MIUDELLA plasma concentrations. No other specific food restrictions; however, limit caffeine intake as it may exacerbate side effects like insomnia or anxiety. |
| Clinical Pearls | MIUDELLA (fictitious drug) is a selective serotonin reuptake inhibitor (SSRI) indicated for major depressive disorder. Onset of therapeutic effect may require 2-4 weeks; assess suicide risk in young adults during initial therapy. Use with caution in patients with hepatic impairment (reduce dose by 50% for Child-Pugh class B/C). Avoid abrupt discontinuation to prevent withdrawal syndrome (taper over 2-4 weeks). |
| Patient Advice | Take MIUDELLA exactly as prescribed at the same time each day, with or without food. · Do not stop taking MIUDELLA suddenly; a gradual dose reduction is required to avoid withdrawal symptoms. · Report worsening depression or suicidal thoughts immediately, especially during the first few months of treatment. · Avoid alcohol consumption while on MIUDELLA as it may increase drowsiness and potentiate central nervous system effects. · Contact your healthcare provider if you experience a rash, hives, or swelling, as these may indicate an allergic reaction. · Inform all healthcare providers that you are taking MIUDELLA, including before any surgery or dental procedure. · Store MIUDELLA at room temperature away from moisture and heat, and keep out of reach of children. |
Loading safety data…